Meeting
2020 ASCO Virtual Scientific Program
Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.
Authors
Michael Weller
Laboratory of Molecular Neuro-Oncology, Department of Neurology, and Neuroscience Center Zürich, University Hospital and University of Zürich, Zürich, Switzerland
Michael Weller , Ekaterina Terksikh , Manuela Silginer , Carsten Krieg , Patrick Roth , Burkhard Becher , Hans-Georg Wirsching
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2548)
DOI
10.1200/JCO.2020.38.15_suppl.2548
Abstract #
2548
Poster Bd #
39
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Donna Molaie
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2015 ASCO Annual Meeting
Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.
First Author: Bogdana Suchorska